Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
Sponsor: Royal United Hospitals Bath NHS Foundation Trust
Summary
The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care. The main questions are: * Do treatment responses differ according to the number of previous advanced therapies? * Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness? Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development. Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.
Official title: STRIDE-PsA: A Study of Treatment Response and Immunogenicity in Sequential Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug (b/tsDMARD) Exposure in Psoriatic Arthritis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2026-03
Completion Date
2026-03
Last Updated
2026-02-23
Healthy Volunteers
No
Conditions
Interventions
Biologic or targeted synthetic DMARD (b/tsDMARD)
This is a non-interventional observational study. Participants will receive biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as part of routine NHS clinical care, and no treatment will be assigned by the study. Participants will be categorised into cohorts according to the line of advanced therapy being initiated at study entry (first line, second/third line, fourth/fifth line, and sixth line or beyond). The study will evaluate treatment outcomes, circulating drug levels, and anti-drug antibody (ADA) status across these treatment-line groups. All treatment decisions remain at the discretion of the treating clinician.
Locations (1)
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom